JNJ: Earnings Apr 14 Test $236 Valuation
At $236.02, Johnson & Johnson sits 6.2% below its 52-week high of $251.71 and 22% above its 200-day moving average of $193.76. That gap between price and long-term trend tells the story of 2025: a company that rewired itself from a consumer-health conglomerate into a focused MedTech and pharmaceutical operator, and a market that repriced the stock accordingly. The question now is whether the April 14 earnings report validates the premium or exposes it. Trailing twelve-month EPS of $11.03 puts the current PE at 21.4x, but strip out the Q1 2025 one-time gain that inflated that quarter's EPS to $4.54, and the underlying run-rate looks closer to $8.70 on a normalized basis. Wall Street's forward consensus of roughly $14.00 for FY2026 implies a forward PE of 16.9x — reasonable for a healthcare name with this balance sheet, but not cheap enough to buy aggressively into a pullback. The pragmatic read: JNJ is a hold at current levels, with the April 14 earnings catalyst determining whether this consolidation resolves higher or stalls out. The MedTech transformation is real, the financials are solid, and the valuation is fair — not a screaming buy, not a sell.